studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 1199A
2031
Impact of pre-treatment platelet count on hepatocellular
carcinoma development during entecavir treatment of
chronic hepatitis B virus infection
Akira Kawano 1 , Hirohisa Shigematsu 1 , Koichiro Miki 1 , Hironori
Tanimoto 2 , Yasunori Ichiki 10 , Chie Morita 3 , Kimihiko Yanagita 4 ,
Kazuhiro Takahashi 5 , Kazufumi Dohmen 6 , Masataka Seike 7 ,
Hideyuki Nomura 2 , Hiromi Ishibashi 8 , Shinji Shimoda 9 ; 1 Department
of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu,
Japan; 2 The Center for Liver Disease, Shin-Kokura Hospital,
Kitakyushu, Japan; 3 Department of Internal Medicine, JR Kyushu
Hospital, Kitakyushu, Japan; 4 Department of Internal Medicine,
Saiseikai Karatsu Hospital, Saga, Japan; 5 Department of Medicine,
Hamanomachi Hospital, Fukuoka, Japan; 6 Department of
Internal Medicine, Chihaya Hospital, Fukuoka, Japan; 7 Department
of Gastroenterology, Oita University, Oita, Japan; 8 Department
of Hepato-Biliary-Pancreatic Medicine, Fukuoka Sanno Hospital,
Fukuoka, Japan; 9 Department of Medicine and Biosystemic Science,
Kyushu University, Fukuoka, Japan; 10 Department of Internal
Medicine, Japan Community Health care Organization Kyushu
Hospital, Kitakyushu, Japan
Background and Aims: Entecavir (ETV) is one of the first-line
nucleoside analogs for treating patients with chronic HBV infection.
The risk of the hepatocellular carcinoma (HCC) development
for ETV-treated patients remains unclear. The objective of
this study was to evaluate the pre-treatment predictors of the
development of HCC in the patients of chronic HBV infection
treated with ETV, and its influence on clinical course. Methods:
This retrospective multicenter study consisted of 151 Japanese
patients with chronic HBV infection who received ETV treatment
more than 12 months. The median age was 51.0 yo and 97
patients (64.2%) were male. Genotype C was the most prevalent
(86.0%). Median HBV DNA was 7.1 log copies (LC)/mL.
Seventy two patients (47.7%) were positive for hepatitis B e
antigen (HBeAg). Median aminotransferase (ALT) level, serum
albumin level, platelet (PLT) count and serum alpha-fetoprotein
(AFP) level were 111 IU/L, 41 g/L, 157 x10 9 /L and 6.6 ng/
mL, respectively. Median treatment duration was 47.4 months.
Results: Fourteen patients developed HCC during follow-up.
The cumulative incidence of HCC at 3, 5, and 7-year was 7.7,
11.4, and 13.3 %, respectively. Multivariate analysis extracted
lower PLT counts (p=0.0055) and higher age (p=0.0133) as
significant independent pre-treatment predictors of the development
of HCC. Cumulative incidence of HCC was significantly
higher in the low PLT group (